Cuvitru Injection, Solution
Product Images NDC 0944-2850

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Cuvitru (NDC 0944-2850). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cuvitru 01

An instructional illustration showing two steps for preparing an injection. The left side depicts a hand removing a seal from a vial. The right side shows a hand drawing solution from the vial into a syringe, demonstrating proper aseptic technique.*

FDA Label Image

Cuvitru 02

An instructional illustration showing three panels of the human body from the back and side. The first two panels indicate recommended subcutaneous injection sites on the upper back and upper arms. The third panel shows a close-up of a hand holding an infusion device, positioned near the abdomen for subcutaneous administration.*

FDA Label Image

Cuvitru 03

An instructional illustration showing the subcutaneous injection technique. The left panel depicts a person inserting a needle at a 90-degree angle into the abdominal skin. The right panel shows the injection site covered with adhesive dressings, with tubing connected to an infusion device on the abdomen.*

FDA Label Image

Cuvitru 04

An instructional illustration showing subcutaneous injection preparation with medical supplies including a syringe, vials, alcohol pads, scissors, and tape on a table. Below, a handwashing step is depicted with hands under running water from a faucet, demonstrating proper hygiene prior to the procedure.*

FDA Label Image

Cuvitru 05

A three-panel illustration demonstrating the preparation of an injection. The first panel shows a hand holding a vial upright. The second panel depicts a hand inserting a swab or cotton pad on the vial's rubber stopper. The third panel illustrates a hand drawing liquid from the vial into a syringe.*

FDA Label Image

Cuvitru 06

An instructional illustration showing a hand holding a syringe with a blue cap and a finger pressing on a black button or release mechanism at the bottom of the syringe barrel. This likely demonstrates a step in preparing or administering a subcutaneous injection drug such as CUVITRU.*

FDA Label Image

Cuvitru 07

An instructional illustration showing the front and back view of a human torso and a detailed image of a hand holding a small white square, demonstrating preparation for subcutaneous injection. This likely relates to the administration of CUVITRU (Immune Globulin Subcutaneous), a plasma derivative injection for subcutaneous use.*

FDA Label Image

Cuvitru 08

An instructional illustration showing the subcutaneous injection process of CUVITRU (Immune Globulin Subcutaneous Human) 200 mg/mL solution. The top image depicts a hand holding a syringe at a 90-degree angle to the skin of the abdomen, preparing for injection. The lower image shows the infusion site on the abdomen covered with a transparent dressing, with an infusion set attached and tubing connected to the site.*

FDA Label Image

Cuvitru 09

An instructional illustration showing a hand holding an injection device above skin labeled with subcutaneous tissue layers. An arrow points upward to indicate the direction for removal or insertion related to a subcutaneous injection procedure.*

FDA Label Image

Cuvitru 10

CUVITRU 20% (Immune Globulin Subcutaneous (Human)) 1g/5mL single-dose vial label. It shows the product name, strength, dosage form as solution for subcutaneous administration, storage instructions including refrigeration and room temperature guidelines, and manufacturer Takeda Pharmaceuticals America, Inc. The label includes lot number, expiration date fields, and usage warnings such as discarding unused portions.*

FDA Label Image

Cuvitru 11

CUVITRU 200 mg/mL Immune Globulin Subcutaneous (Human) injection solution packaging label. The label presents a 5 mL single-dose vial containing 1 g of the solution for subcutaneous administration. It includes storage instructions, manufacturer information as Takeda Pharmaceuticals through Baxalta US Inc., and mentions the product is Rx only. The label design features blue, pink, orange, and black color elements and the Shire logo.*

FDA Label Image

Cuvitru 12

Label for CUVITRU Immune Globulin Subcutaneous (Human) 20%, 2g/10mL injection solution in a single-dose vial. The label includes storage instructions, stating refrigeration at 2°C to 8°C for up to 36 months or room temperature not exceeding 25°C for up to 24 months. The vial stopper is latex-free. Labeler is Takeda Pharmaceuticals America, Inc., with the brand logo Shire visible.*

FDA Label Image

Cuvitru 13

The packaging label for CUVITRU Immune Globulin Subcutaneous (Human) 20% injection, solution, 200 mg/mL. The label indicates a 2g in 10 mL single-dose vial for subcutaneous administration. It includes storage instructions, Rx only designation, and is labeled by Takeda Pharmaceuticals America, Inc., with Shire branding. The label also notes that the product is a plasma derivative and provides contact and manufacturing information.*

FDA Label Image

Cuvitru 14

CUVITRU Immune Globulin Subcutaneous (Human) 20% injection solution at 200 mg/mL in a single-dose 20 mL vial. The label includes storage instructions, manufacturer information (Baxalta US Inc., Lexington, MA), and regulatory details. Marked Rx Only with the Shire logo, indicating prescription use.*

FDA Label Image

Cuvitru 15

Carton label for CUVITRU 200 mg/mL (Immune Globulin Subcutaneous (Human) 20%), a plasma derivative in 20 mL single-dose vials containing 4g of immune globulin. The label indicates subcutaneous injection route, storage instructions, manufacturer Takeda Pharmaceuticals America, Inc., and includes warning and handling information on the blue and white background with orange design elements.*

FDA Label Image

Cuvitru 16

CUVITRU 200 mg/mL Immune Globulin Subcutaneous (Human) injection solution label. It is a single-dose vial containing 8 grams in 40 mL, for subcutaneous administration. The label includes storage instructions, manufacturer listed as Baxalta US Inc. (a subsidiary of Shire plc), and indicates prescription-only use with the NDC 0944-2850-08.*

FDA Label Image

Cuvitru 17

CUVITRU 200 mg/mL Immune Globulin Subcutaneous (Human) injection solution packaging label. The label indicates a 40 mL single-dose vial containing 8g of active ingredient per vial. Manufactured by Takeda Pharmaceuticals America, Inc. The label includes storage conditions, usage instructions, and trademark information for Shire and Baxalta.*

FDA Label Image

Cuvitru 18

CUVITRU Immune Globulin Subcutaneous (Human) 20% injection solution label for subcutaneous administration, 10g in 50 mL single-dose vial. The label includes storage instructions, manufacturer information (Baxalta US Inc., a Shire company), and notes that the vial stopper is not made with natural rubber latex. NDC 0944-2850-10.*

FDA Label Image

Cuvitru 19

Packaging label for CUVITRU 20% (Immune Globulin Subcutaneous (Human)) injection solution, 10g/50mL single-dose vial. The label indicates subcutaneous administration, manufacturer Takeda Pharmaceuticals America, Inc., and provides storage instructions: refrigerate at 2°C to 8°C, or room temperature not to exceed 25°C for specified durations. The product is preservative-free and stabilized with glycine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.